Yb-DTPA, a novel contrast agent in magnetic resonance imaging: application to rat kidney.
We have developed a novel contrast agent, ytterbium-diethylenetriamine pentaacetic acid (Yb-DTPA), for magnetic resonance imaging (MRI) and its mechanism of action is predominantly by the susceptibility mechanism. We have applied this contrast agent for renal MRI studies. We also demonstrate that Yb-DTPA has a renal clearance similar to that of inulin in rats and may therefore be useful for the estimation of glomerular filtration rate.
Sarkar
S K
SK
Department of Physical & Structural Chemistry, Smith Kline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
Rycyna
R E
RE
Lenkinski
R E
RE
Solleveld
H A
HA
Kinter
L B
LB
D000818:Animals; D003287:Contrast Media / Q000138:chemical synthesis; D005682:Gadolinium; D019786:Gadolinium DTPA; D005919:Glomerular Filtration Rate; D007089:Image Enhancement / Q000379:methods; D007444:Inulin / Q000493:pharmacokinetics; D007668:Kidney / Q000033:anatomy & histology* / Q000378:metabolism; D007679:Kidney Medulla / Q000033:anatomy & histology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D015018:Ytterbium / Q000493:pharmacokinetics
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D007444:Inulin; D005682:Gadolinium; D019786:Gadolinium DTPA; D015018:Ytterbium